ABSTRACT
INTRODUCTION CSF α-synuclein seed amplification assay (SAA) is a sensitive and specific tool for detecting Lewy body (LB) co-pathology in AD.
METHODS 1637 cross-sectional and 407 longitudinal CSF samples from ADNI were tested with SAA. We examined longitudinal dynamics of Aβ, α-synuclein seeds, and p-tau181, along with global and domain-specific cognition in stable SAA+, stable SAA−, and those who converted to SAA+ from SAA−.
RESULTS SAA+ individuals had faster cognitive decline than SAA−, notably in MCI, and presented with earlier symptom onset. SAA+ conversion was associated with CSF Aβ42-positivity but did not impact progression of either Aβ42 or p-tau181 status. Aβ42, p-tau181, and α-syn SAA were all strong predictors of clinical progression, particularly Aβ42. In vitro α-syn SAA kinetic parameters were associated with participant demographics, clinical profiles, and cognitive decline.
DISCUSSION These results highlight the interplay between Aβ and α-synuclein and their association with disease progression.
Competing Interest Statement
D.T., Z.H., P.T., and L.M.S. receive funding from NIH/NIA. C.B. have nothing to disclose. L.C.M., J.L., and R.L. are full-time employee of Amprion Inc and hold stock or stock options of Aprion Inc. A.B.S. receives funding from Intramural Research Program of the National Institutes of Health; received honoraria from Movement Disorders Journal and npjParkinson's Disease; received travel support from Chan Zuckerberg Initiative, Michael J Fox Foundation, and Weill Cornell M.W.W. serves on Editorial Boards for Alzheimer's & Dementia, and the Journal for Prevention of Alzheimer's disease. He has served on Advisory Boards for Acumen Pharmaceutical, Alzheon, Inc., Cerecin, Merck Sharp & Dohme Corp., and NC Registry for Brain Health. He also serves on the USC ACTC grant which receives funding from Eisai for the AHEAD study. He has provided consulting to BioClinica, Boxer Capital, LLC, Cerecin, Inc., Clario, Dementia Society of Japan, Eisai, Guidepoint, Health and Wellness Partners, Indiana University, LCN Consulting, Merck Sharp & Dohme Corp., NC Registry for Brain Health, Prova Education, T3D Therapeutics, University of Southern California (USC), and WebMD. He has acted as a speaker/lecturer for China Association for Alzheimer's Disease (CAAD) and Taipei Medical University, as well as a speaker/lecturer with academic travel funding provided by: AD/PD Congress, Cleveland Clinic, CTAD Congress, Foundation of Learning; Health Society (Japan), INSPIRE Project; U. Toulouse, Japan Society for Dementia Research, and Korean Dementia Society, Merck Sharp & Dohme Corp., National Center for Geriatrics and Gerontology (NCGG; Japan), University of Southern California (USC). He holds stock options with Alzeca, Alzheon, Inc., ALZPath, Inc., and Anven. Dr. Weiner received support for his research from the following funding sources: National Institutes of Health (NIH)/NINDS/National Institute on Aging (NIA), Department of Defense (DOD), California Department of Public Health (CDPH), University of Michigan, Siemens, Biogen, Hillblom Foundation, Alzheimer's Association, Johnson & Johnson, Kevin and Connie Shanahan, GE, VUmc, Australian Catholic University (HBI-BHR), The Stroke Foundation, and the Veterans Administration.
Funding Statement
Data analysis for this study was partially funded by NIH/NIA U19AG024904.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
ADNI study was approved by each ADNI study site's respective institutional review board and informed written consents were obtained from all participants. The ADNI data used in this study were obtained from the ADNI database (https://adni.loni.usc.edu). All ADNI data are shared without embargo through the LONI Image and Data Archive (IDA).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
The ADNI data used in this study were obtained from the ADNI database (https://adni.loni.usc.edu). All ADNI data are shared without embargo through the LONI Image and Data Archive (IDA).
